Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Chronic Lymphocytic Leukemia Therapy: Beyond Chemoimmunotherapy

Author(s): Julio Delgado, Tycho Baumann, Gabriela Ghita and Emili Montserrat

Volume 18, Issue 23, 2012

Page: [3356 - 3362] Pages: 7

DOI: 10.2174/138161212801227014

Price: $65

Abstract

Chemoimmunotherapy is the new gold standard of therapy for patients with advanced chronic lymphocytic leukemia (CLL). However, in spite of the high complete response rate achieved with chemoimmunotherapy, all patients eventually relapse and CLL is still incurable. Newer and more rationally developed compounds are clearly needed for these patients, in particular those with refractory disease. Among these agents, novel monoclonal antibodies, cyclin-dependent kinase inhibitors, chromokine receptor antagonists, lenalidomide, signal transduction inhibitors and pro-apoptotic molecules have recently shown some efficacy in patients with relapsed or refractory disease. Hopefully, the combined use of these agents in risk-adapted treatment strategies will improve the outcome of patients with CLL and set the stage for their cure.

Keywords: Chronic lymphocytic leukemia, monoclonal antibodies, microenvironment, chemoimmunotherapy, cyclin-dependent kinase inhibitors, chromokine receptor antagonists, lenalidomide, signal transduction inhibitors, pro-apoptotic molecules, B-cell clone


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy